Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Judd Klingerman's selected project will take him to Madrid, Spain, for six weeks this summer.
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.